Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia

Yvette L. Kasamon, Robert A. Brodsky, Michael J. Borowitz, Richard F. Ambinder, Pamela A. Crilley, Steve Y. Cho, Hua Ling Tsai, B. Douglas Smith, Douglas E. Gladstone, Hetty E. Carraway, Carol Ann Huff, William H. Matsui, Javier Bolaños-Meade, Richard J. Jones, Lode J. Swinnen

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


Older patients with Burkitt lymphoma/leukemia (BL) have inferior outcomes. Because cyclophosphamide is highly active in BL and can be dose-escalated without stem-cell rescue, we designed a short, cyclophosphamide-intensive regimen without anthracyclines for patients aged ≥ 30 with untreated, non-HIV-associated BL/atypical BL. Two cycles involving cyclophosphamide 1500 mg/m2, vincristine, rituximab, prednisone, methotrexate 3 g/m 2, and intrathecal cytarabine were delivered 2 weeks apart, followed by intensification with high-dose cyclophosphamide (50 mg/kg/day for 4 days) and rituximab. Of 21 patients, median age 53 (range, 34-75), 71% had stage IV, 95% were high-risk and 29% had performance status 3-4. Response occurred in all evaluable patients post-cycle 2 and in 76% post-intensification. Five non-relapse deaths occurred (four before intensification). The estimated 1-year and 3-year event-free survival was 52%; 1-year and 3-year overall survival was 57%. Seventeen (81%) received intensification (median 30 days to intensification). Brief, anthracycline-sparing, intensive cyclophosphamide (BASIC) therapy yields durable remissions in poorer-risk BL/atypical BL.

Original languageEnglish (US)
Pages (from-to)483-490
Number of pages8
JournalLeukemia and Lymphoma
Issue number3
StatePublished - Mar 2013


  • Atypical Burkitt lymphoma
  • Burkitt lymphoma
  • Cyclophosphamide
  • Unclassifiable B-cell lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia'. Together they form a unique fingerprint.

Cite this